Biopharmaceutical company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of infectious diseases
Location: United States, New Jersey, Ramsey
Employees: 201-500
Total raised: $26M
Founded date: 2004
Investors 4
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| 06.11.2022 | Hercules C... | htgc.com |
| - | Biomark Ca... | biomarkcap... |
| - | Perceptive... | perceptive... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.06.2015 | - | $21M | - |
| 15.12.2014 | - | $5M | - |
Mentions in press and media 13
| Date | Title | Description |
| 05.03.2024 | ADMA Biologics to Participate in the Raymond James Institutional Investor Conference | - |
| 04.03.2024 | ASCENIV | STN: 125590 Proper Name: Immune Globulin Intravenous, Human-slra Tradename: ASCENIV Manufacturer: ADMA Biologics, Inc. Indication: Treatment of Primary Immunodeficiency Diseases (PIDD) Product Information Supporting Documents Related Inform... |
| 22.02.2024 | ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics | ADMAlytics Combines Generative AI and Machine Learning to Optimize Production Processes ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, anno... |
| 10.05.2023 | ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update | 1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement Achieved Milestone First-Time Positive Adjusted EBITDA (1), Totaling $2.5 Million, Earlier Than Forecasted FY2023 Total Reve... |
| 11.11.2021 | ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments - Form 8-K | ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020 Achiev... |
| 11.11.2021 | ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments | Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020 Achieved First-Time Positive Gross Profit Narrowed Net Losses Quarter-Over-Quarter Management to Host Conference Call and We... |
| 25.10.2021 | ADMA Biologics : Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares | RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biolo... |
| 21.10.2021 | ADMA Biologics : Announces Pricing of Public Offering for $50 Million of Common Stock | RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing spec... |
| 21.10.2021 | ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock | RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing spec... |
| 21.10.2021 | ADMA Biologics : Announces Pricing of Public Offering for $50 Million of Common Stock - Form 8-K | ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock RAMSEY, N.J. and BOCA RATON, Fla., October 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a... |
Show more